Intravenous thrombolysis (IVT) and endovascular thrombectomy (EVT) both improve outcomes for patients with acute ischemic stroke. Jeffrey L. Saver, MD, director of UCLA’s Comprehensive Stroke and Vascular Neurology Program and a JAMA Associate Editor, discusses 2 randomized trials comparing outcomes for stroke patients treated with IVT prior to EVT vs EVT alone.

Related Article:

Intravenous Thrombolysis Before Endovascular Thrombectomy for Acute Ischemic Stroke

Interview with Raina M. Merchant, MD, author of Public Health Messaging in an Era of Social Media

Interview with Michael Silverstein, MD, MPH, USPSTF member and coauthor of USPSTF Recommendation: Tobacco Cessation in Adults

The COVID-19 pandemic has prompted scientists to use adaptive research designs to evaluate potential treatments simultaneously and efficiently, increasing the likelihood that patients will receive treatments most likely to be effective for them. Lennie Derde, MD, of University Medical Center Utrecht in the Netherlands and JAMA Associate Editor Christopher W. Seymour, MD, of University of Pittsburgh Medical Center join JAMA's Q&A series to discuss the latest in critical care management of COVID-19 patients and emerging treatment strategies and therapies. Recorded January 13, 2021.

Related Article(s):

Sensible Medicine-Optimizing the Trade-off Between Learning and Doing in a Pandemic

Arnold S. Monto, MD, chaired the US Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee (VRBPAC) meetings in December that led to Emergency Use Authorization (EUA) of the Pfizer/BioNTech and Moderna vaccines. He joins JAMA's Q&A series from the University of Michigan School of Public Health to discuss experience to date with the 2 products and what's next in vaccine development. Recorded January 11, 2021.

Related Article(s):

Experts Discuss COVID-19: Vaccine Allocation, Placebo Groups, and More

Increasing the number of physicians who are Black, Hispanic/Latinx, and Indigenous benefits everyone in the US, but it cannot be the sole responsibility of historically Black colleges and universities (HBCUs). Valerie Montgomery Rice, MD, president and dean of Morehouse School of Medicine (MSM), and Clyde W. Yancy, MD, of Northwestern Medicine, join JAMA Editor in Chief Howard Bauchner, MD, to discuss options for developing training pipelines of underrepresented minority health science students, and how academic medicine can make racial justice a part of its work and mission. Recorded January 5, 2021.

Related Article:

Academic Medicine and Black Lives Matter

The National Academy of Medicine's 2000 report "To Err Is Human" launched the health care quality movement in the US. Victor Dzau, MD, president of the National Academy of Medicine, and Don Berwick, MD, MPP, from the Institute for Healthcare Improvement, discuss progress to date in advancing quality and prospects for improving outcomes and reducing harms, errors, and cost in the next 20 years. Recorded December 22, 2020.

Related Article(s):

Two Decades Since To Err Is Human

Interview with Geoffrey S. Ginsburg, MD, PhD, author of Digital Health—The Need to Assess Benefits, Risks, and Value

With coronavirus vaccines now available, what are the timeline and prospects for "herd immunity" and return to a new normal? Marc Lipsitch, DPhil, of Harvard T.H. Chan School of Public Health returns to JAMA's Q&A series with Paul D. Biddinger, MD, director of Massachusetts General Hospital's Center for Disaster Medicine, to discuss. Recorded December 17, 2020.

Related Article(s):

• COVID-19 Vaccines and Herd Immunity
• The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials
• Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines
• Herd Immunity and Implications for SARS-CoV-2 Control
• Herd Immunity as a Coronavirus Pandemic Strategy

Peter W. Marks, MD, PhD, and Stephen M. Hahn, MD, return to JAMA's Q&A series to discuss the Pfizer/BioNTech and Moderna vaccines: the data, the weekend's EUA designation (Pfizer/BioNTech), and the process for future full licensure and postmarketing safety surveillance.

Dr Marks directs the US FDA's Center for Biologics Evaluation and Research (CBER). Dr Hahn is commissioner of the US Food and Drug Administration. Recorded December 14, 2020.

Related Article(s):

Behaviorally Informed Strategies for a National COVID-19 Vaccine Promotion Program